Abstract
The Bacillus anthracis lethal factor (LF) is one component of a tripartite exotoxin partly responsible for persistent anthrax cytotoxicity after initial bacterial infection. Inhibitors of the zinc metalloproteinase have been investigated as potential therapeutic agents, but LF is a challenging target because inhibitors lack sufficient selectivity or possess poor pharmaceutical properties. These structural studies reveal an alternate conformation of the enzyme, induced upon binding of specific inhibitors, that opens a previously unobserved deep pocket termed S1′∗ which might afford new opportunities to design selective inhibitors that target this subsite.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3836-3841 |
| Number of pages | 6 |
| Journal | FEBS Letters |
| Volume | 589 |
| Issue number | 24 |
| DOIs | |
| State | Published - Dec 21 2015 |
Bibliographical note
Publisher Copyright:© 2015 Federation of European Biochemical Societies.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Anthrax
- Conformational change
- Lethal factor
- Ligand-induced
- Structure-based drug design
- Zinc hydrolase
Fingerprint
Dive into the research topics of 'Ligand-induced expansion of the S1′ site in the anthrax toxin lethal factor'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS